Telesis Bio (TBIO) 10-Q 11 Aug 21 2021 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Jun. 30, 2021	Jul. 31, 2021
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2021
Document Transition Report	false
Entity File Number	001-40497
Entity Registrant Name	CODEX DNA, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	45-1216839
Entity Address, Address Line One	9535 Waples Street
Entity Address, Address Line Two	Suite 100
Entity Address, City or Town	San Diego
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92121
City Area Code	858
Local Phone Number	228-4115
Title of 12(b) Security	Common Stock, $0.0001 par value per share
Trading Symbol	DNAY
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		29,291,743
Entity Central Index Key	0001850079
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q2

Condensed Consolidated Balance

Condensed Consolidated Balance Sheet - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 123,771	$ 13,463
Accounts receivable, net of allowance for bad debts of $0 and $105 at June 30, 2021 and December 31, 2020, respectively	1,922	2,266
Inventory	1,052	601
Prepaid expenses and other current assets	554	851
Total current assets	127,299	17,181
Property and equipment, net	665	689
Right-of-use assets	2,775	3,090
Long-term deposits	81	81
Goodwill	3,497	3,497
Other intangible assets, net	2,100	2,325
Total Assets	136,417	26,863
Current liabilities:
Accounts payable	2,061	1,191
Accrued employee expenses	2,172	1,470
Success fee contingent liability	750	0
Finance lease liability, current portion	83	90
Operating lease liability, current portion	739	693
Deferred revenue, current portion	417	606
Other accrued liabilities	541	220
Notes payable, current portion	0	1,333
Other current liabilities	54	22
Total current liabilities	6,817	5,625
Finance lease liability, net of current portion	39	81
Operating lease liability, net of current portion	2,397	2,776
Notes payable, net of discount and current portion	14,485	3,353
Derivative liabilities	134	1,533
Deferred revenue, net of current portion	108	40
Total liabilities	23,980	13,408
Commitments and contingencies (Note 13)
Convertible preferred stock
Convertible preferred stock	0	38,914
Stockholders' equity (deficit)
Preferred stock, $.0001 par value; 5,000,000 and 0 shares authorized at June 30, 2021 and December 31, 2020, respectively. No shares issued and outstanding	0	0
Common stock, $.0001 par value; 100,000,000 and 72,000,000 shares authorized at June 30, 2021 and December 31, 2020, respectively; 29,291,563 and 5,023,957 shares issued and outstanding at June 30, 2021 and December 31, 2020,respectively	5	2
Additional paid-in capital	155,387	851
Accumulated deficit	(42,955)	(26,312)
Total stockholders' equity (deficit)	112,437	(25,459)
Total liabilities, convertible preferred stock and stockholders' equity (deficit)	136,417	26,863
Series Z Convertible Preferred Stock
Convertible preferred stock
Convertible preferred stock	0	1
Series A Convertible Preferred Stock
Convertible preferred stock
Convertible preferred stock	0	20,992
Series A-1 Convertible Preferred Stock
Convertible preferred stock
Convertible preferred stock	$ 0	$ 17,921

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheet (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Assets
Allowance for bad debts	$ 0	$ 105
Convertible preferred stock
Convertible preferred stock, shares outstanding (in shares)	0	15,079,329
Stockholders' equity (deficit)
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	5,000,000	0
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	72,000,000	100,000,000
Common stock, shares issued (in shares)	29,291,563	5,023,957
Common stock, shares outstanding (in shares)	29,291,563	5,023,957
Series Z Convertible Preferred Stock
Convertible preferred stock
Convertible preferred stock, par or stated value per share (in dollars per share)	$ 0.0001	$ 0.0001
Convertible preferred stock, shares authorized (in shares)	0	7,500,000
Convertible preferred stock, shares issued (in shares)	0	2,500,000
Convertible preferred stock, shares outstanding (in shares)	0	2,500,000
Series A Convertible Preferred Stock
Convertible preferred stock
Convertible preferred stock, par or stated value per share (in dollars per share)	$ 0.0001	$ 0.0001
Convertible preferred stock, shares authorized (in shares)	0	22,797,830
Convertible preferred stock, shares issued (in shares)	0	7,599,274
Convertible preferred stock, shares outstanding (in shares)	0	7,599,274
Series A-1 Convertible Preferred Stock
Convertible preferred stock
Convertible preferred stock, par or stated value per share (in dollars per share)	$ 0.0001	$ 0.0001
Convertible preferred stock, shares authorized (in shares)	0	15,402,237
Convertible preferred stock, shares issued (in shares)	0	4,980,055
Convertible preferred stock, shares outstanding (in shares)	0	4,980,055

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Revenue:
Total revenue	$ 2,852,000	$ 1,617,000	$ 5,179,000	$ 3,004,000
Cost of revenue	1,899,000	620,000	2,924,000	1,194,000
Gross profit	953,000	997,000	2,255,000	1,810,000
Operating expenses:
Research and development	2,746,000	1,955,000	5,624,000	3,918,000
Sales and marketing	2,630,000	1,598,000	4,905,000	2,897,000
General and administrative	3,149,000	740,000	5,562,000	1,886,000
Total operating expenses	8,525,000	4,293,000	16,091,000	8,701,000
Loss from operations	(7,572,000)	(3,296,000)	(13,836,000)	(6,891,000)
Other income (expense):
Interest expense, net	(379,000)	(141,000)	(620,000)	(333,000)
Change in fair value of derivative liabilities	(1,251,000)	(574,000)	(1,547,000)	(667,000)
Loss on extinguishment of debt	0	0	(618,000)	0
Other income (expense), net	3,000	(71,000)	(16,000)	(71,000)
Total other expense, net	(1,627,000)	(786,000)	(2,801,000)	(1,071,000)
Loss before provision for income taxes	(9,199,000)	(4,082,000)	(16,637,000)	(7,962,000)
Provision for income taxes	(2,000)	0	(6,000)	0
Net loss	(9,201,000)	(4,082,000)	(16,643,000)	(7,962,000)
Comprehensive loss	(9,201,000)	(4,082,000)	(16,643,000)	(7,962,000)
Net loss attributable to common stockholders	(9,201,000)	(4,082,000)	(16,643,000)	(7,962,000)
Net loss attributable to common stockholders	$ (9,201,000)	$ (4,082,000)	$ (16,643,000)	$ (7,962,000)
Net loss per share attributable to common stock holders
Basic (in dollars per share)	$ (1,060)	$ (820)	$ (2,390)	$ (1,590)
Diluted (in dollars per share)	$ (1,060)	$ (820)	$ (2,390)	$ (1,590)
Weighted average common stock outstanding
Basic (in shares)	8,697,707	5,000,286	6,955,084	5,000,143
Diluted (in shares)	8,697,707	5,000,286	6,955,084	5,000,143
Product sales
Revenue:
Total revenue	$ 2,120,000	$ 1,387,000	$ 3,919,000	$ 2,435,000
Royalties and other revenue
Revenue:
Total revenue	$ 732,000	$ 230,000	$ 1,260,000	$ 569,000

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Accumulated Deficit
Balance at beginning of period (in shares) at Dec. 31, 2019	15,079,329
Balance at beginning of period at Dec. 31, 2019	$ 38,914
Balance at end of period (in shares) at Mar. 31, 2020	15,079,329
Balance at end of period at Mar. 31, 2020	$ 38,914
Balance at beginning of period (in shares) at Dec. 31, 2019		5,000,000
Balance at beginning of period at Dec. 31, 2019	(7,503)	$ 2	$ 797	$ (8,302)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation expense	15		15
Net loss	(3,880)			(3,880)
Balance at end of period (in shares) at Mar. 31, 2020		5,000,000
Balance at end of period at Mar. 31, 2020	$ (11,368)	$ 2	812	(12,182)
Balance at beginning of period (in shares) at Dec. 31, 2019	15,079,329
Balance at beginning of period at Dec. 31, 2019	$ 38,914
Balance at end of period (in shares) at Jun. 30, 2020	15,079,329
Balance at end of period at Jun. 30, 2020	$ 38,914
Balance at beginning of period (in shares) at Dec. 31, 2019		5,000,000
Balance at beginning of period at Dec. 31, 2019	(7,503)	$ 2	797	(8,302)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(7,962)
Balance at end of period (in shares) at Jun. 30, 2020		5,000,329
Balance at end of period at Jun. 30, 2020	$ (15,440)	$ 2	822	(16,264)
Balance at beginning of period (in shares) at Mar. 31, 2020	15,079,329
Balance at beginning of period at Mar. 31, 2020	$ 38,914
Balance at end of period (in shares) at Jun. 30, 2020	15,079,329
Balance at end of period at Jun. 30, 2020	$ 38,914
Balance at beginning of period (in shares) at Mar. 31, 2020		5,000,000
Balance at beginning of period at Mar. 31, 2020	(11,368)	$ 2	812	(12,182)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options (in shares)		329
Stock-based compensation expense	10		10
Net loss	(4,082)			(4,082)
Balance at end of period (in shares) at Jun. 30, 2020		5,000,329
Balance at end of period at Jun. 30, 2020	$ (15,440)	$ 2	822	(16,264)
Balance at beginning of period (in shares) at Dec. 31, 2020	15,079,329
Balance at beginning of period at Dec. 31, 2020	$ 38,914
Balance at end of period (in shares) at Mar. 31, 2021	15,079,329
Balance at end of period at Mar. 31, 2021	$ 38,914
Balance at beginning of period (in shares) at Dec. 31, 2020	5,023,957	5,023,957
Balance at beginning of period at Dec. 31, 2020	$ (25,459)	$ 2	851	(26,312)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options (in shares)		223,216
Issuance of Common Stock upon exercise of stock options	133		133
Stock-based compensation expense	67		67
Net loss	(7,442)			(7,442)
Balance at end of period (in shares) at Mar. 31, 2021		5,247,173
Balance at end of period at Mar. 31, 2021	$ (32,701)	$ 2	1,051	(33,754)
Balance at beginning of period (in shares) at Dec. 31, 2020	15,079,329
Balance at beginning of period at Dec. 31, 2020	$ 38,914
Balance at end of period (in shares) at Jun. 30, 2021	0
Balance at end of period at Jun. 30, 2021	$ 0
Balance at beginning of period (in shares) at Dec. 31, 2020	5,023,957	5,023,957
Balance at beginning of period at Dec. 31, 2020	$ (25,459)	$ 2	851	(26,312)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon exercise of stock options (in shares)	269,145
Net loss	$ (16,643)
Balance at end of period (in shares) at Jun. 30, 2021	29,291,563	29,291,563
Balance at end of period at Jun. 30, 2021	$ 112,437	$ 5	155,387	(42,955)
Balance at beginning of period (in shares) at Mar. 31, 2021	15,079,329
Balance at beginning of period at Mar. 31, 2021	$ 38,914
Convertible Preferred Stock
Conversion of convertible preferred shares into an equivalent number of common shares (in shares)	(15,079,329)
Conversion of convertible preferred shares into an equivalent number of common shares	$ (38,914)
Balance at end of period (in shares) at Jun. 30, 2021	0
Balance at end of period at Jun. 30, 2021	$ 0
Balance at beginning of period (in shares) at Mar. 31, 2021		5,247,173
Balance at beginning of period at Mar. 31, 2021	(32,701)	$ 2	1,051	(33,754)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common shares upon initial public offering, net of issuance costs		7,666,664
Issuance of common shares upon initial public offering, net of issuance costs of $8,587	112,484	$ 1	112,483
Conversion of convertible preferred shares into an equivalents number of common shares (in shares)		15,079,329
Conversion of convertible preferred shares into an equivalent number of common shares	38,914	$ 2	38,912
Issuance of common stock upon exercise of stock options (in shares)		1,252,468
Issuance of warrant and conversion into common shares	2,770		2,770
Issuance of common stock upon exercise of stock options (in shares)		45,929
Issuance of Common Stock upon exercise of stock options	25		25
Stock-based compensation expense	146		146
Net loss	$ (9,201)			(9,201)
Balance at end of period (in shares) at Jun. 30, 2021	29,291,563	29,291,563
Balance at end of period at Jun. 30, 2021	$ 112,437	$ 5	$ 155,387	$ (42,955)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Cash Flows From Operating Activities:
Net loss	$ (16,643)	$ (7,962)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	189	208
Amortization of intangible assets	225	238
Amortization of debt discount	274	106
Loss on extinguishment of debt	618	0
Loss on disposal of intangible asset	0	73
Stock-based compensation	213	25
Amortization of operating lease right-of-use assets	315	290
Change in fair value of derivative liabilities	1,547	667
Non-cash interest on finance leases	(7)	(10)
Changes in assets and liabilities:
Accounts receivable	344	354
Inventories	(451)	(124)
Deposits, prepaid expenses and other current assets	297	(355)
Accounts payable, accrued payroll and accrued liabilities	1,925	(276)
Deferred revenue	(121)	120
Operating lease liabilities	(333)	(209)
Net cash used in operating activities	(11,608)	(6,855)
Cash Flows From Investing Activities:
Purchase of property and equipment	(165)	(106)
Net cash used in investing activities	(165)	(106)
Cash Flows From Financing Activities:
Borrowings on term loan	14,872	0
Repayment of term loan	(5,000)	0
Debt extinguishment costs	(391)	0
Payments on finance leases	(42)	(54)
Proceeds from the exercise of common stock options	158	0
Net proceeds from issuance of common shares in initial public offering	112,484	0
Net cash provided by (used in) financing activities	122,081	(54)
Net Increase (Decrease) In Cash	110,308	(7,015)
Cash and cash equivalents at beginning of period	13,463	29,144
Cash and cash equivalents at end of period	123,771	22,129
Supplemental Disclosure Of Cash Flow Information:
Cash paid for interest	270	228
Purchases of property and equipment included in accounts payable	0	32
Initial public offering costs in accounts payable	363	0
Issuance of preferred stock warrant in connection with term loan	322	0
Extinguishment of put option derivative liability in connection with term loan	(51)	0
Issuance of put option derivative liability in connection with term loan	303	0
Conversion of convertible preferred shares into common shares	38,914	0
Conversion of warrant into common shares	$ 2,770	$ 0

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical) $ in Thousands	3 Months Ended
	Jun. 30, 2021USD ($)
Statement of Stockholders' Equity [Abstract]
Payments of Stock Issuance Costs	$ 8,587

Organization and Operations

Organization and Operations	6 Months Ended
	Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
ORGANIZATION AND OPERATIONS	ORGANIZATION AND OPERATIONS Business Codex DNA, Inc. (the Company) was incorporated in the state of Delaware in March 2011, as Synthetic Genomics Solution, Inc., a wholly owned subsidiary of Synthetic Genomics, Inc. (SGI). The Company changed its name to SGI-DNA, Inc. (SGI-DNA) in February 2013, and then to Codex DNA, Inc. in June 2020. SGI-DNA Limited, a United Kingdom company focused on sales and marketing activities, is a wholly owned subsidiary of Codex DNA, Inc. The Company manufactures and sells laboratory equipment, specifically synthetic biology instruments, reagents and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. On March 8, 2019, SGI sold SGI-DNA to GATTACA Mining, LLC (Purchaser or GATTACA) by entering into a stock purchase agreement to sell all of the Company’s outstanding common and preferred stock in exchange for a $10 million non-recourse promissory note. Both the Company and Purchaser are co-borrowers of the promissory note. As this transaction was a change in control transaction in accordance with generally accepted accounting principles in the United States (US GAAP), the Company elected to apply push-down accounting and recognized a step up in the basis of the assets acquired and liabilities assumed in the acquisition. On June 10, 2021, the Company’s Board of Directors and stockholders approved a 3-for-1 reverse stock split of the Company’s issued and outstanding common stock and outstanding shares of convertible preferred stock, which was effected on June 11, 2021. The reverse stock split also applied to all outstanding securities or rights convertible into, or exchangeable or exercisable for, common stock or convertible preferred stock. Accordingly, all shares, stock options, warrants and per share information presented in the accompanying consolidated financial statements and notes thereto have been retroactively adjusted to reflect the reverse stock split. There was no change in the par value and authorized number of shares of the Company’s common stock or preferred stock. On June 18, 2021, the Company completed an initial public offering (IPO) of 7,666,664 shares of its common stock, including the exercise in full by the underwriters of their option to purchase up to 999,999 additional shares of common stock, for aggregate gross proceeds of $122.7 million. The Company’s shares began trading on the Nasdaq Global Select Market under the ticker symbol “DNAY” on June 18, 2021. The Company received $112.5 million in net proceeds after deducting underwriting discounts and commissions and other offering expenses payable by the Company. Upon closing of the IPO, all outstanding convertible preferred stock converted into 15,079,329 shares of common stock and SGI’s outstanding warrants were automatically exercised into 1,201,059 shares of common stock. Since its inception, the Company has devoted substantially all of its efforts to raising capital, commercializing its current products, and developing new product offerings. The Company is subject to a number of risks similar to those of other companies conducting high-risk, early-stage research and development of products. Principal among these risks are a dependence on key individuals and intellectual property, competition from other products and companies, and the technical risks associated with the successful research, development and manufacturing of its products. The Company’s success is dependent upon its ability to continue to raise additional capital in order to fund ongoing research and development, commercialize its products, generate revenue, meet its obligations, and, ultimately, become profitable. Products currently under development will require significant additional research and development efforts. These efforts require significant amounts of additional capital, adequate personnel and infrastructure. The Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date the 2020 consolidated financial statements were issued. Since inception, the Company has incurred cumulative operating losses and negative cash flows from operations. These operating losses and negative cash flows have been financed principally from the issuance of equity securities and debt. The Company’s ability to continue as a going concern is dependent upon the ability to raise additional debt or equity capital. There can be no assurance that such capital will be available in sufficient amounts or on terms acceptable to the Company. Risks to which the Company is exposed include uncertainties related to the ability to achieve revenue-generating products; current and potential competitors with greater financial, technological, production, and marketing resources; dependence on key management personnel; and raising additional capital, as needed. Based upon the Company’s current plans, management believes there currently is sufficient financial resources to fund the Company’s operations for at least twelve months from the issuance date of these financial statements. The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty. Impact of COVID-19 In December 2019, a novel strain of coronavirus, which causes the disease known as COVID-19, was reported to have surfaced in Wuhan, China. Since then, COVID-19 coronavirus has spread globally. In June 2020, the World Health Organization declared the COVID-19 outbreak a pandemic. The ongoing COVID-19 global and national health emergency has caused significant disruption in the international and United States economies and financial markets. The spread of COVID-19 has caused illness, quarantines, cancellation of events and travel, business and school shutdowns, reduction in business activity and financial transactions, labor shortages, supply chain interruptions and overall economic and financial market instability. In response to public health directives and orders and to help minimize the risk of the virus to employees, the Company has taken precautionary measures, including implementing work-from-home policies for certain employees. The COVID-19 pandemic has the potential to significantly impact the Company’s manufacturing supply chain, distribution or logistics and other services. Additionally, the Company’s service providers and their operations may be disrupted, temporarily closed or experience worker or supply shortages, which could result in additional disruptions or delays in shipments of laboratory equipment or the advancement of the scientific research. To date, the Company is not aware of any such disruptions. Furthermore, to date, the Company has not experienced the pandemic’s adverse impacts in any material respect. The Company is not able to estimate the duration of the pandemic or potential impact on the business if disruptions or delays in shipments of product occur. In addition, a severe prolonged economic downturn could result in a variety of risks to the business, including weakened demand for product and a decreased ability to raise additional capital when needed on acceptable terms, if at all. As the situation continues to evolve, the Company will continue to closely monitor market conditions and respond accordingly.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation and Principles of Consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (U.S. GAAP) and included the accounts of the Company and its wholly owned subsidiary after the elimination of all significant intercompany accounts and transactions. Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (ASC) and as amended by Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB). The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited annual consolidated financial statements as of and for the year ended December 31, 2020, and, in the opinion of management, reflect all adjustments, consisting of normal recurring adjustments, necessary for the fair presentation of the Company’s condensed consolidated balance sheet as of June 30, 2021, the condensed consolidated statements of operations and comprehensive loss, condensed consolidated statements of convertible preferred stock and stockholders’ equity (deficit) for the three and six months ended June 30, 2021 and 2020, and the condensed consolidated statements of cash flows for the six months ended June 30, 2021 and 2020. The accompanying condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and the accompanying notes for the year ended December 31, 2020 included in the Company’s final prospectus that forms part of the Company’s Registration Statement on Form S-1, filed with the Securities and Exchange Commission (SEC) pursuant to Rule 424(b)(4) on June 21, 2021 (the Prospectus). The condensed consolidated balance sheet data as of December 31, 2020 presented for comparative purposes was derived from the Company’s audited consolidated financial statements but does not include all disclosures required by U.S. GAAP. The Company’s significant accounting policies are disclosed in the audited consolidated financial statements for the year ended December 31, 2020 included in the Prospectus. Since the date of the audited consolidated financial statements for the year ended December 31, 2020 included in the Prospectus, there have been no changes to its significant accounting policies except as noted below. Unaudited Interim Financial Information The accompanying condensed consolidated balance sheet as of June 30, 2021, the condensed consolidated statements of operations and comprehensive loss, the condensed consolidated statements of convertible preferred stock and stockholders’ equity (deficit) for the three and six months ended June 30, 2021 and 2020, and the condensed consolidated statements of cash flows for the six months ended June 30, 2021 and 2020 are unaudited. The unaudited interim consolidated financial statements have been prepared on the same basis as the audited annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary for the fair statement of the Company’s financial position as of June 30, 2021 and the results of its operations or the three and six months ended June 30, 2021 and 2020, and its cash flows for the six months ended June 30, 2021 and 2020. The financial data and other information disclosed in these notes related to the three and six months ended June 30, 2021 and 2020 are also unaudited. The results for the three and six months ended June 30, 2021 are not necessarily indicative of results to be expected for the year ending December 31, 2021, any other interim periods, or any future year or period. Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting periods presented. Key estimates in the consolidated financial statements include the Company’s ability to continue as a going concern, revenue recognition, impairment assessment for goodwill and intangible assets, allowance for doubtful accounts, estimated useful lives of property and equipment, valuation of inventory, accrued expenses, valuation of deferred income tax assets, valuation of derivative liabilities, share-based compensation and accrued warranty are subject to significant estimation. Actual results could differ from those estimates. Revenue Recognition Product Revenue, Net The Company recognizes revenue on product sales to customers when the transfer of control happens, which generally occurs upon shipment. The Company recognizes revenue on installation and training when the service has been rendered. The Company includes a standard one year warranty with its product sales.These standard warranties are accounted for at the time product revenues are recognized. The Company also offers extended warranty for an additional fee. Revenue related to extended warranty is recognized on a straight-line basis over the term. Product revenues are recorded net of variable consideration, including discounts. Warranty Obligations The company estimates its cost of standard product warranties, primarily from historical information, and records a charge in cost of revenues at the time product revenues are recognized. The Company’s estimated warranty obligation at June 30, 2021 was $26,000 and is included in other current liabilities in our condensed consolidated balance sheet.

Fair Value Measurement

Fair Value Measurement	6 Months Ended
	Jun. 30, 2021
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENT	FAIR VALUE MEASUREMENT The following table summarizes the fair values of the Company’s assets and liabilities on the condensed consolidated balance sheets which comprise money market funds and the participation right liability, warrant liability, contingent put option liability, and success fee contingent liability (in thousands): Fair value measurements as of June 30, 2021 Level 1 Level 2 Level 3 Total Assets Money market funds $ 123 $ — $ — $ 123 Total $ 123 $ — $ — $ 123 Liabilities Contingent put option liability $ — $ — $ 134 $ 134 Success fee contingent liability 750 — — 750 Total $ 750 $ — $ 134 $ 884 Fair value measurements as of December 31, 2020 Level 1 Level 2 Level 3 Total Liabilities Participation right liability $ — $ — $ 420 $ 420 Warrant liability — — 594 594 Contingent put option liability — — 51 51 Success fee contingent liability — — 468 468 Total $ — $ — $ 1,533 $ 1,533 During the six months ended June 30, 2021, transfers into Level 1 from Level 3 were as a result of changes in the observability of significant inputs and quoted prices of the success fee contingent liability. During the year ended December 31, 2020 there were no transfers between Level 1, Level 2 and Level 3. Participation Right Liability The quantitative elements associated with the Company’s Level 3 inputs impacting the fair value measurement of the participation right liability include management’s expectation of amounts to be raised and the probability of success in obtaining the funds. The fair value was determined by multiplying the amount expected to be raised versus the probability of success and the percentage right (3%). As of June 30, 2021 and December 31, 2020, the fair value of the participation r ight was valued at $0 due to the liability’s extinguishment pursuant to the Company’s IPO and $0.4 million, respectively. Preferred Stock Warrants The preferred stock warrant liability consists of the fair value of warrants to purchase Series A-1 Preferred Stock issued in conjunction with the Series A-1 financing in December 2019 with SGI and the 2021 Loan Agreement (See Note 8) and was based on significant inputs not observable in the market, which represent a Level 3 measurement within the fair value hierarchy. As of December 31, 2020, the fair value of the Series A-1 convertible preferred stock warrant was $3.87 per share. Upon the closing of the IPO, SGI’s outstanding preferred stock warrants were automatically exercised into 119,315 shares of common stock. Subsequent to the closing of the IPO, all outstanding warrants issued pursuant to the 2021 Loan Agreement were exercised into 51,409 shares of common stock. As of June 30, 2021, there were no outstanding preferred stock warrants. As of June 18, 2021, the SGI preferred stock warrant was valued by calculating the intrinsic value of the warrant upon the closing of the IPO. The following reflects the significant quantitative inputs used in the valuation of the SGI preferred stock warrant liability as of December 31, 2020: December 31, 2020 Risk-free interest rate 0.1 % Expected term 2.0 years Expected volatility 83.6 % Expected dividend yield 0.0 % The following reflects the significant quantitative inputs used in the valuation of the preferred stock warrants issued pursuant to the 2021 Loan Agreement as of June 18, 2021: June 18, 2021 Risk-free interest rate 1.4 % Expected term 9.7 years Expected volatility 56.0 % Expected dividend yield 0.0 % Contingent Put Option Liability The contingent put option liability consists of the fair value of the contingent interest feature and acceleration clause (contingent put option) under the 2019 Loan Agreement and 2021 Loan Agreement (see Note 8). The fair value of the contingent put option liability was based on significant inputs not observable in the market, which represent a Level 3 measurement within the fair value hierarchy. The Company’s valuation of the contingent put option liability utilized a risk-neutral valuation model wherein the fair value of the underlying debt facility is estimated, both with and without the presence of the default provisions, holding all other assumptions constant. The Company assesses these assumptions and estimates at least annually as additional information impacting the assumptions are obtained. Changes in the fair value of the contingent put option liability are recognized in other income (expense) as part of the change in fair value of derivative liabilities in the condensed consolidated statements of operations and comprehensive loss. Success Fee Contingent Liability The success fee contingent liability consists of the fair value of contingent obligation to pay the lender a success fee of $0.8 million upon a Liquidity Event under the 2019 Loan Agreement (see Note 8). Due to the Company’s IPO on June 18, 2021, the fair value of the success fee contingent liability as of June 30, 2021 is classified as a Level 1 input due to the use of an observable market quote in an active market. As of December 31, 2020, the fair value of the success fee contingent liability was based on significant inputs not observable in the market, which represent a Level 3 measurement within the fair value hierarchy. The Company’s valuation of the success fee contingent liability utilized a liquidity event scenario analysis discounted at the Company’s cost of capital. This analysis consists of both the probability adjusted fair value of the success fee based on liquidity scenarios, and the risk adjusted present value of the success fee discounted at the Company’s cost of capital on the valuation date, to take into account the risk of achieving the liquidity scenarios. The Company assesses these assumptions and estimates at least annually as additional information impacting the assumptions are obtained. Changes in the fair value of the success fee contingent liability are recognized in other income (expense) as part of the change in fair value of derivative liabilities in the condensed consolidated statement of operations and comprehensive loss. The following table provides a roll-forward of the aggregate fair value of the Company’s derivative liabilities for which fair value is determined using Level 3 inputs (in thousands): Participation right liability Warrant liability Contingent put liability Success fee contingent liability Fair value at December 31, 2020 $ 420 $ 594 $ 51 $ 468 Extinguishment of liability — — (51) — Issuance of liability — 322 303 — Change in fair value (30) 198 — 128 Fair value at March 31, 2021 390 1,114 303 596 Change in fair value — 1,656 (169) 154 Extinguishment of liability (390) (2,770) — — Transfer out of Level 3 to Level 1 — — — (750) Fair value at June 30, 2021 $ — $ — $ 134 $ — For the three months ended June 30, 2021 and 2020 and six months ended June 30, 2021 and 2020, the Company recorded a change in fair value of derivative liabilities included in other income (expense) of $1.3 million, $0.6 million, $1.5 million, and $0.7 million, respectively.

Inventory

Inventory	6 Months Ended
	Jun. 30, 2021
Inventory Disclosure [Abstract]
INVENTORY	INVENTORY Inventories include material, labor and overhead and are stated at the lower of cost (first-in and first-out method) or net realizable value. The components of inventory are as follows as of June 30, 2021 and December 31, 2020 (in thousands): June 30, December 31, 2020 Raw materials $ 514 $ 299 Work in process and sub-assemblies 414 201 Finished goods 124 101 Total $ 1,052 $ 601

Property and Equipment

Property and Equipment	6 Months Ended
	Jun. 30, 2021
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT	PROPERTY AND EQUIPMENT Property and equipment consisted of the following on June 30, 2021 and December 31, 2020 (in thousands): June 30, December 31, 2020 Machinery and equipment $ 1,552 $ 1,315 Computer hardware and software 6 6 Leasehold improvements 59 32 Construction in progress — 102 Total 1,617 1,455 Less: Accumulated depreciation and amortization (952) (766) Total property and equipment, net $ 665 $ 689 Depreciation expense for the each of the three months ended June 30, 2021 and 2020 was $0.1 million and depreciation expense for the each of the six months ended June 30, 2021 and 2020 was $0.2 million, and is included in operating expenses.

Goodwill and Other Intangible A

Goodwill and Other Intangible Assets	6 Months Ended
	Jun. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
GOODWILL AND OTHER INTANGIBLE ASSETS	GOODWILL AND OTHER INTANGIBLE ASSETS Goodwill As part of the March 8, 2019 transaction (see Note 1), the Company acquired its intangible assets with resulting goodwill. The goodwill carries a fair value of approximately $3.5 million. Due to the recent decline in global economic and labor market conditions caused by the global outbreak of the COVID-19 pandemic, the Company considered the effects on its goodwill and determined that there was no material significant impact that would cause the goodwill to be impaired. There were no other events or circumstances that have changed since the last annual assessment that could reduce the fair value of the Company’s reporting segments below its carrying values. For the three and six months ended June 30, 2021 and 2020, the Company did not record any impairment of goodwill. Other Intangible Assets Other intangible assets include the rights to technology and the SGI-DNA trade name. The Company engaged an independent consultant to value the intangible assets and to determine the useful lives. The technology was valued at approximately $3.2 million with a seven three Amortization expense for each of the three months ended June 30, 2021 and 2020 was approximately $0.1 million and for each of the six months ended June 30, 2021 and 2020 was approximately $0.2 million. The following table summarizes the estimated future amortization expense of the intangible assets as of June 30, 2021 (in thousands): Years ending December 31: 2021 $ 225 2022 450 2023 450 2024 450 2025 450 Thereafter 75 Total $ 2,100

Leases

Leases	6 Months Ended
	Jun. 30, 2021
Leases [Abstract]
LEASES	LEASESAs of June 30, 2021, the Company had three outstanding leases for office and scientific manufacturing equipment. The leases have terms between 25 and 60 months. The components of lease cost under ASC 842 are as follows (in thousands): June 30, June 30, Lease costs Finance lease cost: Payment of finance lease liability $ 42 $ 54 Interest on lease liabilities 7 10 Amortization of right-of-use asset 315 290 Variable lease cost 251 161 Total lease cost $ 615 $ 515 Supplemental disclosure of cash flow information related to leases are as follows (in thousands): June 30, June 30, Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 478 $ 380 Operating cash flows from finance leases $ 7 $ 10 Financing cash flows from finance leases $ 42 $ 54 The weighted-average remaining lease term and discount rate were as follows: June 30, June 30, Weighted-average remaining lease term Finance leases 1.5 years 2.2 years Operating leases 3.6 years 4.6 years Weighted-average discount rate Finance leases 7.7 % 8.0 % Operating leases 8.9 % 8.9 % The following table summarizes the minimum lease payments of the Company’s operating and finance lease liabilities as of June 30, 2021 (in thousands): Year Ending December 31, Operating Finance 2021 $ 489 $ 44 2022 997 85 2023 1,026 — 2024 1,057 — 2025 89 — Total future minimum lease payments 3,658 129 Less: imputed interest (522) (7) Present value of operating lease liability $ 3,136 $ 122 Less: current portion of lease liability (739) (83) Non-current portion of lease liability 2,397 39
LEASES	LEASESAs of June 30, 2021, the Company had three outstanding leases for office and scientific manufacturing equipment. The leases have terms between 25 and 60 months. The components of lease cost under ASC 842 are as follows (in thousands): June 30, June 30, Lease costs Finance lease cost: Payment of finance lease liability $ 42 $ 54 Interest on lease liabilities 7 10 Amortization of right-of-use asset 315 290 Variable lease cost 251 161 Total lease cost $ 615 $ 515 Supplemental disclosure of cash flow information related to leases are as follows (in thousands): June 30, June 30, Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 478 $ 380 Operating cash flows from finance leases $ 7 $ 10 Financing cash flows from finance leases $ 42 $ 54 The weighted-average remaining lease term and discount rate were as follows: June 30, June 30, Weighted-average remaining lease term Finance leases 1.5 years 2.2 years Operating leases 3.6 years 4.6 years Weighted-average discount rate Finance leases 7.7 % 8.0 % Operating leases 8.9 % 8.9 % The following table summarizes the minimum lease payments of the Company’s operating and finance lease liabilities as of June 30, 2021 (in thousands): Year Ending December 31, Operating Finance 2021 $ 489 $ 44 2022 997 85 2023 1,026 — 2024 1,057 — 2025 89 — Total future minimum lease payments 3,658 129 Less: imputed interest (522) (7) Present value of operating lease liability $ 3,136 $ 122 Less: current portion of lease liability (739) (83) Non-current portion of lease liability 2,397 39

Notes Payable

Notes Payable	6 Months Ended
	Jun. 30, 2021
Debt Disclosure [Abstract]
NOTES PAYABLE	NOTES PAYABLE Loan and Security Agreement As of June 30, 2021 and December 31, 2020, the loans payable on the condensed consolidated balance sheets pertains to the Loan and Security Agreement with Silicon Valley Bank and the Loan and Security Agreement with Oxford, respectively, and consists of the following (in thousands): June 30, December 31, 2020 Principal amount of loans payable $ 15,000 $ 5,000 Less: Current portion of loans payable — (1,333) Loans payable, net of current portion 15,000 3,667 Accrued Interest 91 90 Final debt payment liability 400 287 Debt discount and financing costs, net of accretion (1,006) (691) Loans payable, net of discount and current portion $ 14,485 $ 3,353 2019 Loan and Security Agreement On September 5, 2019, we entered into a Loan and Security Agreement with Oxford Finance LLC as the lender (the 2019 Loan Agreement). Under the 2019 Loan Agreement we borrowed a total of $5.0 million in secured loans. These loans were repaid in full in March 2021 with the proceeds from the 2021 Loan Agreement. In connection with the repayment, the Company recognized a loss on debt extinguishment of $0.6 million. These loans bore interest at the greater of (i) 8.79% per annum and (ii) the sum of (a) the thirty (30) day U.S. LIBOR rate reported in The Wall Street Journal on the last Business Day of the month that immediately precedes the month in which the interest will accrue, plus (b) 6.38%. They would have matured on October 1, 2023 and were secured by substantially all of our assets, other than our intellectual property, which was subject to a negative pledge. Payments on the loans were interest-only until May 1, 2021, followed by equal monthly principal payments and accrued interest through the scheduled maturity date of October 1, 2023. In connection with the 2019 Loan Agreement, we have a contingent obligation to pay Oxford a success fee of $0.8 million upon the completion of our IPO. We have also identified a bifurcated compound derivative liability related to a contingent interest feature and acceleration clause (contingent put option). The fair value of the success fee and the contingent put option were recorded within derivative liabilities on our consolidated balance sheets and corresponding discount to the loans under the 2019 Loan Agreement. We remeasure both liabilities to fair value at each reporting date, and we recognize changes in the fair value as a component of other income (expense) in our consolidated statements of operations and comprehensive loss. We will continue to recognize changes in the fair value of the success fee contingent liability until the success fee is paid. The contingent put option liability was extinguished when the 2019 Loan Agreement was terminated in March 2021. 2021 Loan Agreement On March 4, 2021, the Company entered into a Loan and Security Agreement with Silicon Valley Bank (SVB) as the lender (the 2021 Loan Agreement). Under the 2021 Loan Agreement, the Company borrowed a $15.0 million senior secured term loan, the proceeds of which were used to repay all existing obligations under the 2019 Loan Agreement, with the remaining proceeds available for working capital and general corporate purposes. Under the 2021 Loan Agreement, SVB may elect to make a second term loan to the Company in a principal amount up to but not exceeding $5.0 million, as SVB may determine in its sole discretion. In connection with the 2021 Loan Agreement, the Company issued to SVB a warrant to purchase a number of shares of preferred stock (the Preferred Warrant). The Preferred Warrant was exercisable into the number of preferred shares equal to approximately $0.2 million divided by the applicable warrant price. The Preferred Warrant also provides for the grant of additional shares upon the disbursement of an advance under the 2021 Loan Agreement. Such additional shares will be equal to 1.5% of the principal amount of the advance divided by the warrant price. The Preferred Warrant wass exercisable at the original purchase price of the Series A-1 convertible preferred stock. When the Series A-1 convertible preferred stock in which the warrant would have been exercisable into converted into common stock, the warrant holder gained the right to exercise the warrant for such number of shares of common stock into which the preferred shares would have converted into had they been exercised prior to the conversion. The Preferred Warrant was exercised in June 2021 in exchange for 51,409 shares of common stock. The term loans bear interest at a per annum rate equal to the greater of (a) 4.0% above the prime rate and (b) 7.25%. The interest rate as of March 5, 2021 was 7.25% per annum. The loans are secured by substantially all of the Company’s assets, other than intellectual property. The Company has agreed not to encumber its intellectual property assets, except as permitted by the 2021 Loan Agreement. For the six months ended June 30, 2021, the effective interest rate on outstanding borrowings was approximately 10.40%. The term loans mature on January 1, 2024; provided, the loan maturity date will be extended by one year to January 1, 2025, if SVB is satisfied that the Company has achieved at least $4.0 million in trailing three-month instruments and reagents revenue for any three-month period occurring after March 4, 2021 but ending on or before December 31, 2021, subject to confirmatory lender calls. Payments on the term loans are interest-only until February 1, 2022, followed by equal principal payments and monthly accrued interest payments through the scheduled maturity date; provided, the interest-only period may be extended to August 1, 2022 if SVB is satisfied that we have achieved at least $4.0 million in trailing three-month instruments and reagents revenue for any three-month period occurring after March 4, 2021, but ending on or before December 31, 2021, subject to confirmatory lender calls. The Company may elect to prepay the term loans, in whole but not in part, at any time. If the Company elects to voluntarily prepay the term loans before the scheduled maturity date, the Company is required to pay the lender a prepayment fee, equal to 3.0% of the then outstanding principal balance if the prepayment occurs on or before March 4, 2022, 2.0% of the outstanding principal balance if the prepayment occurs after March 4, 2022, but on or before March 4, 2023, or 1.0% of the outstanding principal balance if the prepayment occurs after March 4, 2023, but on or before the scheduled maturity date. No prepayment fee is applicable to a mandatory prepayment of the loans upon an acceleration of the loans. Upon a voluntary or mandatory prepayment of the loans, the Company is also required to pay SVB’s expenses and all accrued but unpaid interest on the loans through the prepayment date. A final payment (the Final Payment) equal to $0.4 million will be due at the earlier of the maturity date, acceleration of the loans, or a voluntary or mandatory prepayment of the loans. The Final Payment is being accrued through interest expense using the effective interest method. Under the 2021 Loan Agreement, the Company agrees to maintain as of the last day of each month, certain consolidated trailing three-month minimum revenue levels as set forth in the 2021 Loan Agreement. The 2021 Loan Agreement includes customary representations and covenants that, subject to exceptions and qualifications, restrict the Company’s ability to do the following things: engage in mergers, acquisitions, and asset sales; transact with affiliates; undergo a change in control; engage in businesses that are not related to the Company’s existing business; add or change business locations; incur additional indebtedness; incur additional liens; make loans and investments; declare dividends or redeem or repurchase equity interests; and make certain amendments or payments in respect of any subordinated debt. In addition, the 2021 Loan Agreement contains customary affirmative covenants, including covenants regarding the payment of taxes and other obligations, maintenance of insurance, maintenance of our bank accounts, protection of our intellectual property, reporting requirements, compliance with applicable laws and regulations, and formation or acquisition of new subsidiaries. The Company is in compliance with its covenants as of June 30, 2021. The 2021 Loan Agreement also includes customary indemnification obligations and customary events of default, including, among other things, payment defaults, breaches of covenants following any applicable cure period, material misrepresentations, a failure of the loans or the lender’s security interest in the collateral to have the priority as required under the 2021 Loan Agreement, a material adverse change as defined in the 2021 Loan Agreement (including without limitation as a result of a government approval having been revoked, rescinded, suspended, modified or not renewed), certain material judgments and attachments, and events relating to bankruptcy or insolvency. The 2021 Loan Agreement also contains a cross default provision under which, if a third party (under any agreement) has a right to accelerate indebtedness greater than $0.5 million, the Company would be in default of the 2021 Loan Agreement. During the continuance of an event of default, SVB may apply a default interest rate of an additional 5% to the outstanding loan balances, and SVB may declare all outstanding obligations immediately due and payable and may exercise other rights and remedies as set forth in the 2021 Loan Agreement and related loan documents. Acceleration would result in the payment of all outstanding loans, any default interest charged by the lender, all expenses of the lender and the Final Payment. The Company bifurcated a compound derivative liability related to the contingent interest feature and acceleration clause (contingent put option) under the 2021 Loan Agreement. The contingent put option liability was valued and separately accounted for in the Company’s condensed consolidated financial statements. The contingent put option liability is classified as a component of derivative liabilities on the condensed consolidated balance sheet. As of June 30, 2021, the estimated fair value of the contingent put option liability was $0.1 million, which was determined by using a risk-neutral valuation model wherein the fair value of the underlying debt facility is estimated, both with and without the presence of the default provisions, holding all other assumptions constant (see Note 3). The estimated future principal payments due under the 2021 Loan Agreement were as follows: June 30, 2021 Estimated future principal payments due 2022 $ 2,500 2023 6,000 2024 6,000 2025 500 Total $ 15,000

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
	Jun. 30, 2021
Share-based Payment Arrangement [Abstract]
STOCK-BASED COMPENSATION	STOCK-BASED COMPENSATION For the three months ended June 20, 2021 and 2020 and the six months ended June 20, 2021 and 2020, the Company recorded stock-based compensation expense of approximately $0.1 million, $10,000, $0.2 million, and $25,000, respectively. No income tax benefit was recognized in the accompanying condensed consolidated statements of operations and comprehensive loss for the Company’s equity incentive plan. The Company’s Board of Directors approved the adoption of the SGI-DNA, Inc. 2019 Stock Plan (the 2019 Plan) in March 2019. The 2019 Plan permitted the Company to grant up to 5,544,187 shares for options and restricted stock units of the Company’s common stock. On March 3, 2021, the Company’s Board of Directors and stockholders approved the termination of the 2019 Plan and the adoption of the 2021 Equity Incentive Plan (the 2021 Plan). 6,000,000 common shares are reserved for issuance under the 2021 Plan. The 2021 Plan provides for the grant of incentive and non-statutory stock options to employees, non-employee directors and consultants of the Company. Options granted under the 2019 Plan and 2021 Plan generally become exercisable over a 4-year period following the date service begins and expire 10 years from the date of grant. The exercise price of incentive stock options granted under the 2019 Plan and 2021 Plan must be at least equal to 100% of the fair value of the Company’s common stock at the date of the grant, except for greater than 10% stockholders for which the exercise price of incentive stock options granted under the 2019 Plan and 2021 Plan must be at least equal to 110% of the fair value of the Company’s common stock at the date of the grant, as determined by the Board of Directors. The exercise price of non-statutory options granted under the 2019 Plan and 2021 Plan must be at least equal to 100% of the fair value of the Company’s common stock at the date of grant, as determined by the Board of Directors. The 2019 Plan and 2021 Plan granted the Company a right of first refusal to repurchase shares issued under the plan at a price set by the optionee, which right terminated upon the IPO. As of June 30, 2021 and December 31, 2020, there were no outstanding shares subject to these repurchase rights. Effective in connection with the IPO, the Company established the 2021 Stock Incentive Plan (the 2021 SIP), which reserved 3,500,000 shares of common stock for future issuance, and the 2021 Employee Stock Purchase Plan (the ESPP), which reserved 350,000 shares of common stock reserved for future issuance. Stock option activity under the 2019 Plan and 2021 Plan for the six months ended June 30, 2021 is as follows: Number of options Weighted average exercise price Weighted average remaining contractual term (in years) Aggregate intrinsic value (in thousands) Balances at December 31, 2020 760,159 $ 0.60 8.7 $ 2,884 Options granted 1,813,829 5.51 9.8 29,419 Options exercised (269,145) 0.59 8.1 5,763 Options cancelled (145,842) 2.41 9.2 2,856 Balances at June 30, 2021 2,159,001 $ 4.83 9.5 $ 37,071 Vested and expected to vest at June 30, 2021 2,159,001 $ 4.83 9.5 $ 37,071 Exercisable at June 30, 2021 82,300 $ 0.51 8.0 $ 1,769 There were 1,813,829 options granted during the six months ended June 30, 2021. The weighted average grant date calculated fair value of options granted during the six months ended June 30, 2021 was $2.16 per share. The calculated value of option grants during the six months ended June 30, 2021 was estimated using the Black-Scholes option pricing model with the following weighted average assumptions: June 30, Risk free interest rate 1.2 % Expected dividend yield — % Expected term 6.1 years Expected volatility 38.8 % Stock-based compensation expense related to stock options was classified in the condensed consolidated statements of operations and comprehensive loss as follows (in thousands): Three months ended June 30, 2021 Six months ended June 30, 2021 Research and development $ 4 $ 7 Sales and marketing 15 30 General and administrative 127 176 Total $ 146 $ 213 As of June 30, 2021, total unrecognized stock-based compensation expense related to unvested stock-based awards was $3.8 million, which is expected to be recognized over a weighted average period of 3.4 years.

STOCKHOLDER'S EQUITY

STOCKHOLDER'S EQUITY	6 Months Ended
	Jun. 30, 2021
Equity [Abstract]
Stockholders' Equity	STOCKHOLDERS’ EQUITYOn June 18, 2021, the Company completed its IPO of 7,666,664 shares of its common stock, including the exercise in full by the underwriters of their option to purchase up to 999,999 additional shares of common stock, for aggregate gross proceeds of $122.7 million. The Company’s common stock began trading on the Nasdaq Global Select Market under the ticker symbol “DNAY” on June 18, 2021. The Company received $112.5 million in net proceeds after deducting underwriting discounts and commissions and other offering expenses payable by the Company. Upon closing of the IPO, all outstanding convertible preferred stock converted into 15,079,329 common shares and SGI’s outstanding warrants were automatically exercised into 1,201,059 shares of common stock. Subsequent to the closing of the IPO, all outstanding warrants issued pursuant to the 2021 Loan Agreement were exercised into 51,409 shares of common stock.

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2021
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES The Company estimates an annual effective tax rate of 0% for the year ending December 31, 2021 as the Company incurred losses for the six months ended June 30, 2021 and is forecasting additional losses through the remainder of fiscal year ending December 31, 2021, resulting in an estimated net loss for both financial statement and tax purposes for the year ending December 31, 2021. Therefore, no federal or state income taxes are expected and none have been recorded at this time. Income taxes have been accounted for using the liability method. Due to the Company’s history of losses since inception, there is not enough evidence at this time to support that the Company will generate future income of a sufficient amount and nature to utilize the benefits of its net deferred tax assets. Accordingly, the deferred tax assets have been reduced by a full valuation allowance, since the Company does not currently believe that realization of its deferred tax assets is more likely than not. As of June 30, 2021, the Company had no unrecognized income tax benefits that would reduce the Company’s effective tax rate if recognized.

Commitment and Contingencies

Commitment and Contingencies	6 Months Ended
	Jun. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES Litigation The Company may become involved in various claims, suits, and legal proceedings from time to time in the ordinary course of its business. The Company accrues a liability when it believes that it is both probable and the amount of loss can be reasonably estimated. While the outcome of such claims, lawsuits or other proceedings cannot be predicted with certainty, management expects that any liability, to the extent not provided for by insurance or otherwise, will not have a material adverse effect on the Company’s consolidated financial position or results of operations. Codexis Trademark Litigation In May 2020 Codexis, Inc. (Codexis) filed a complaint against the Company relating to its CODEX DNA name based on Codexis’ rights in the CODEX and CODEXIS mark in the U.S. District Court, Northern District of California for federal and common law trademark infringement and unfair competition/false designation (the Complaint). Codexis seeks injunctive relief, including that the Company cease all use of the term CODEX and any other trademark confusingly similar to the marks CODEX and CODEXIS and not apply for registration of or register the CODEX mark or any other mark confusingly similar to the CODEX or CODEXIS marks, transfer to Codexis all domain names and social media accounts/user names that include the term “codex” and pay damages (consisting of Codexis’s actual damages, a disgorgement of the Company’s profits and punitive damages as permitted by California common law) as well as attorneys’ fees and costs. A case management status conference is scheduled with the court on August 20, 2021. If the Company cannot resolve this matter with Codexis, then a jury trial is set for March 2022. Eurofins Pharma Non-Competition/Non-Solicitation Litigation In October 2018, Eurofins Pharma US Holdings II, Inc. (EPUSH II) and Eurofins DiscoverX Corporation (Eurofins DiscoverX) (collectively, Plaintiffs) filed a complaint against Todd R. Nelson, SGI-DNA, Inc. (SGI-DNA, which is the Company’s prior name) and Synthetic Genomics, Inc. (the Company’s former parent company, and together with Dr. Nelson and SGI-DNA, the Defendants) to enforce non-competition and non-solicitation provisions of an agreement. The complaint, filed in the Superior Court of California, County of San Diego, charges Dr. Nelson with breach of contract, SGI-DNA with tortious interference, and both with unfair competition. The complaint seeks permanent injunctive relief, monetary damages and other equitable relief (including restitution) against the Defendants. The civil jury trial, initially scheduled for April 24, 2020, has been rescheduled to August 27, 2021. The Company has not accrued a liability for either matter as it does not believe a liability is probable. Contingencies As described in the Note 8 above, the Company has a success fee contingent liability to a creditor that will require a payment of $0.8 million. This contingent liability was recorded at its fair value of $0.8 million and $0.5 million at June 30, 2021 and December 31, 2020, respectively. Leases The Company’s non-cancelable lease commitments are described in Note 7.

Net Loss Per Share

Net Loss Per Share	6 Months Ended
	Jun. 30, 2021
Earnings Per Share [Abstract]
NET LOSS PER SHARE	NET LOSS PER SHARE Net loss per share Basic and diluted net loss per share attributable to common stockholders was calculated as follows (in thousands, except share and per share amounts:): Three months ended June 30, Six months ended June 30, 2021 2020 2021 2020 Numerator: Net loss $ (9,201) $ (4,082) $ (16,643) $ (7,962) Net loss attributable to common stockholders $ (9,201) $ (4,082) $ (16,643) $ (7,962) Denominator: Weighted average common stock outstanding - basic and diluted 8,697,707 5,000,286 6,955,084 5,000,143 Net loss per share attributable to common stockholders - basic and diluted $ (1.06) $ (0.82) $ (2.39) $ (1.59) The Company’s potential dilutive securities have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential common shares from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect: June 30, 2021 2020 Series Z convertible preferred stock (as converted to common stock) — 2,500,000 Series A convertible preferred stock (as converted to common stock) — 7,599,274 Series A-1 convertible preferred stock (as converted to common stock) — 4,980,055 Warrants to purchase common stock — 1,081,745 Warrants to purchase Series A-1 convertible preferred stock (as converted to common stock) — 154,022 Stock options to purchase common stock 2,159,001 856,555 Total 2,159,001 17,171,651

Retirement Plan

Retirement Plan	6 Months Ended
	Jun. 30, 2021
Retirement Benefits [Abstract]
RETIREMENT PLAN	RETIREMENT PLANThe Company has a retirement saving plan (the 401(k) Plan) that allows participating employees to defer a portion of their annual compensation on a pretax basis. The Company made no contributions to the 401(k) Plan for the six months ended June 30, 2021 and 2020.

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2021
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	RELATED PARTY TRANSACTIONSDuring the six months ended June 30, 2021 and 2020, the Company made payments to related parties of approximately $0.1 million and $0.2 million, respectively, for payments to board members and services relating to intellectual property matters, including patent filings and patent prosecution.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2021
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	SUBSEQUENT EVENTSOn July 15, 2021, OUM & CO. LLP (OUM), the Company’s independent registered public accountants, combined its practice with that of WithumSmith + Brown, PC (Withum). Effective July 16, 2021, the Company, after review and approval of the Company’s Audit Committee, appointed Withum as the Company’s new independent registered public accounting firm for and with respect to the fiscal year ending December 31, 2021.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Basis of Presentation	The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (U.S. GAAP) and included the accounts of the Company and its wholly owned subsidiary after the elimination of all significant intercompany accounts and transactions. Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (ASC) and as amended by Accounting Standards Updates (ASU) of the Financial Accounting Standards Board (FASB).
Principle of Consolidation	The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited annual consolidated financial statements as of and for the year ended December 31, 2020, and, in the opinion of management, reflect all adjustments, consisting of normal recurring adjustments, necessary for the fair presentation of the Company’s condensed consolidated balance sheet as of June 30, 2021, the condensed consolidated statements of operations and comprehensive loss, condensed consolidated statements of convertible preferred stock and stockholders’ equity (deficit) for the three and six months ended June 30, 2021 and 2020, and the condensed consolidated statements of cash flows for the six months ended June 30, 2021 and 2020. The accompanying condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and the accompanying notes for the year ended December 31, 2020 included in the Company’s final prospectus that forms part of the Company’s Registration Statement on Form S-1, filed with the Securities and Exchange Commission (SEC) pursuant to Rule 424(b)(4) on June 21, 2021 (the Prospectus). The condensed consolidated balance sheet data as of December 31, 2020 presented for comparative purposes was derived from the Company’s audited consolidated financial statements but does not include all disclosures required by U.S. GAAP. The Company’s significant accounting policies are disclosed in the audited consolidated financial statements for the year ended December 31, 2020 included in the Prospectus. Since the date of the audited consolidated financial statements for the year ended December 31, 2020 included in the Prospectus, there have been no changes to its significant accounting policies except as noted below.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting periods presented. Key estimates in the consolidated financial statements include the Company’s ability to continue as a going concern, revenue recognition, impairment assessment for goodwill and intangible assets, allowance for doubtful accounts, estimated useful lives of property and equipment, valuation of inventory, accrued expenses, valuation of deferred income tax assets, valuation of derivative liabilities, share-based compensation and accrued warranty are subject to significant estimation. Actual results could differ from those estimates.
Revenue Recognition	Product Revenue, Net The Company recognizes revenue on product sales to customers when the transfer of control happens, which generally occurs upon shipment. The Company recognizes revenue on installation and training when the service has been rendered. The Company includes a standard one year warranty with its product sales.These standard warranties are accounted for at the time product revenues are recognized. The Company also offers extended warranty for an additional fee. Revenue related to extended warranty is recognized on a straight-line basis over the term. Product revenues are recorded net of variable consideration, including discounts. Warranty Obligations The company estimates its cost of standard product warranties, primarily from historical information, and records a charge in cost of revenues at the time product revenues are recognized. The Company’s estimated warranty obligation at June 30, 2021 was $26,000 and is included in other current liabilities in our condensed consolidated balance sheet.
Inventory	Inventories include material, labor and overhead and are stated at the lower of cost (first-in and first-out method) or net realizable value.

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	6 Months Ended
	Jun. 30, 2021
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The following table summarizes the fair values of the Company’s assets and liabilities on the condensed consolidated balance sheets which comprise money market funds and the participation right liability, warrant liability, contingent put option liability, and success fee contingent liability (in thousands): Fair value measurements as of June 30, 2021 Level 1 Level 2 Level 3 Total Assets Money market funds $ 123 $ — $ — $ 123 Total $ 123 $ — $ — $ 123 Liabilities Contingent put option liability $ — $ — $ 134 $ 134 Success fee contingent liability 750 — — 750 Total $ 750 $ — $ 134 $ 884 Fair value measurements as of December 31, 2020 Level 1 Level 2 Level 3 Total Liabilities Participation right liability $ — $ — $ 420 $ 420 Warrant liability — — 594 594 Contingent put option liability — — 51 51 Success fee contingent liability — — 468 468 Total $ — $ — $ 1,533 $ 1,533
Fair Value Measurement Inputs and Valuation Techniques	The following reflects the significant quantitative inputs used in the valuation of the SGI preferred stock warrant liability as of December 31, 2020: December 31, 2020 Risk-free interest rate 0.1 % Expected term 2.0 years Expected volatility 83.6 % Expected dividend yield 0.0 % The following reflects the significant quantitative inputs used in the valuation of the preferred stock warrants issued pursuant to the 2021 Loan Agreement as of June 18, 2021: June 18, 2021 Risk-free interest rate 1.4 % Expected term 9.7 years Expected volatility 56.0 % Expected dividend yield 0.0 %
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation	The following table provides a roll-forward of the aggregate fair value of the Company’s derivative liabilities for which fair value is determined using Level 3 inputs (in thousands): Participation right liability Warrant liability Contingent put liability Success fee contingent liability Fair value at December 31, 2020 $ 420 $ 594 $ 51 $ 468 Extinguishment of liability — — (51) — Issuance of liability — 322 303 — Change in fair value (30) 198 — 128 Fair value at March 31, 2021 390 1,114 303 596 Change in fair value — 1,656 (169) 154 Extinguishment of liability (390) (2,770) — — Transfer out of Level 3 to Level 1 — — — (750) Fair value at June 30, 2021 $ — $ — $ 134 $ —

Inventory (Tables)

Inventory (Tables)	6 Months Ended
	Jun. 30, 2021
Inventory Disclosure [Abstract]
Schedule of Inventory	The components of inventory are as follows as of June 30, 2021 and December 31, 2020 (in thousands): June 30, December 31, 2020 Raw materials $ 514 $ 299 Work in process and sub-assemblies 414 201 Finished goods 124 101 Total $ 1,052 $ 601

Property and Equipment (Tables)

Property and Equipment (Tables)	6 Months Ended
	Jun. 30, 2021
Property, Plant and Equipment [Abstract]
Property and Equipment	Property and equipment consisted of the following on June 30, 2021 and December 31, 2020 (in thousands): June 30, December 31, 2020 Machinery and equipment $ 1,552 $ 1,315 Computer hardware and software 6 6 Leasehold improvements 59 32 Construction in progress — 102 Total 1,617 1,455 Less: Accumulated depreciation and amortization (952) (766) Total property and equipment, net $ 665 $ 689

Goodwill and Other Intangible_2

Goodwill and Other Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2021
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense	The following table summarizes the estimated future amortization expense of the intangible assets as of June 30, 2021 (in thousands): Years ending December 31: 2021 $ 225 2022 450 2023 450 2024 450 2025 450 Thereafter 75 Total $ 2,100

Leases (Tables)

Leases (Tables)	6 Months Ended
	Jun. 30, 2021
Leases [Abstract]
Lease, Cost	The components of lease cost under ASC 842 are as follows (in thousands): June 30, June 30, Lease costs Finance lease cost: Payment of finance lease liability $ 42 $ 54 Interest on lease liabilities 7 10 Amortization of right-of-use asset 315 290 Variable lease cost 251 161 Total lease cost $ 615 $ 515 Supplemental disclosure of cash flow information related to leases are as follows (in thousands): June 30, June 30, Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 478 $ 380 Operating cash flows from finance leases $ 7 $ 10 Financing cash flows from finance leases $ 42 $ 54 The weighted-average remaining lease term and discount rate were as follows: June 30, June 30, Weighted-average remaining lease term Finance leases 1.5 years 2.2 years Operating leases 3.6 years 4.6 years Weighted-average discount rate Finance leases 7.7 % 8.0 % Operating leases 8.9 % 8.9 %
Lessee, Operating Lease, Liability, Maturity	The following table summarizes the minimum lease payments of the Company’s operating and finance lease liabilities as of June 30, 2021 (in thousands): Year Ending December 31, Operating Finance 2021 $ 489 $ 44 2022 997 85 2023 1,026 — 2024 1,057 — 2025 89 — Total future minimum lease payments 3,658 129 Less: imputed interest (522) (7) Present value of operating lease liability $ 3,136 $ 122 Less: current portion of lease liability (739) (83) Non-current portion of lease liability 2,397 39
Finance Lease, Liability, Fiscal Year Maturity	The following table summarizes the minimum lease payments of the Company’s operating and finance lease liabilities as of June 30, 2021 (in thousands): Year Ending December 31, Operating Finance 2021 $ 489 $ 44 2022 997 85 2023 1,026 — 2024 1,057 — 2025 89 — Total future minimum lease payments 3,658 129 Less: imputed interest (522) (7) Present value of operating lease liability $ 3,136 $ 122 Less: current portion of lease liability (739) (83) Non-current portion of lease liability 2,397 39

Notes Payable (Tables)

Notes Payable (Tables)	6 Months Ended
	Jun. 30, 2021
Debt Disclosure [Abstract]
Schedule of Long-term Debt Instruments	As of June 30, 2021 and December 31, 2020, the loans payable on the condensed consolidated balance sheets pertains to the Loan and Security Agreement with Silicon Valley Bank and the Loan and Security Agreement with Oxford, respectively, and consists of the following (in thousands): June 30, December 31, 2020 Principal amount of loans payable $ 15,000 $ 5,000 Less: Current portion of loans payable — (1,333) Loans payable, net of current portion 15,000 3,667 Accrued Interest 91 90 Final debt payment liability 400 287 Debt discount and financing costs, net of accretion (1,006) (691) Loans payable, net of discount and current portion $ 14,485 $ 3,353
Schedule of Maturities of Long-term Debt	The estimated future principal payments due under the 2021 Loan Agreement were as follows: June 30, 2021 Estimated future principal payments due 2022 $ 2,500 2023 6,000 2024 6,000 2025 500 Total $ 15,000

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2021
Share-based Payment Arrangement [Abstract]
Share-based Payment Arrangement, Option, Activity	Stock option activity under the 2019 Plan and 2021 Plan for the six months ended June 30, 2021 is as follows: Number of options Weighted average exercise price Weighted average remaining contractual term (in years) Aggregate intrinsic value (in thousands) Balances at December 31, 2020 760,159 $ 0.60 8.7 $ 2,884 Options granted 1,813,829 5.51 9.8 29,419 Options exercised (269,145) 0.59 8.1 5,763 Options cancelled (145,842) 2.41 9.2 2,856 Balances at June 30, 2021 2,159,001 $ 4.83 9.5 $ 37,071 Vested and expected to vest at June 30, 2021 2,159,001 $ 4.83 9.5 $ 37,071 Exercisable at June 30, 2021 82,300 $ 0.51 8.0 $ 1,769
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	The calculated value of option grants during the six months ended June 30, 2021 was estimated using the Black-Scholes option pricing model with the following weighted average assumptions: June 30, Risk free interest rate 1.2 % Expected dividend yield — % Expected term 6.1 years Expected volatility 38.8 %
Share-based Payment Arrangement, Expensed and Capitalized, Amount	Stock-based compensation expense related to stock options was classified in the condensed consolidated statements of operations and comprehensive loss as follows (in thousands): Three months ended June 30, 2021 Six months ended June 30, 2021 Research and development $ 4 $ 7 Sales and marketing 15 30 General and administrative 127 176 Total $ 146 $ 213

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	6 Months Ended
	Jun. 30, 2021
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	Basic and diluted net loss per share attributable to common stockholders was calculated as follows (in thousands, except share and per share amounts:): Three months ended June 30, Six months ended June 30, 2021 2020 2021 2020 Numerator: Net loss $ (9,201) $ (4,082) $ (16,643) $ (7,962) Net loss attributable to common stockholders $ (9,201) $ (4,082) $ (16,643) $ (7,962) Denominator: Weighted average common stock outstanding - basic and diluted 8,697,707 5,000,286 6,955,084 5,000,143 Net loss per share attributable to common stockholders - basic and diluted $ (1.06) $ (0.82) $ (2.39) $ (1.59)
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The Company excluded the following potential common shares from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect: June 30, 2021 2020 Series Z convertible preferred stock (as converted to common stock) — 2,500,000 Series A convertible preferred stock (as converted to common stock) — 7,599,274 Series A-1 convertible preferred stock (as converted to common stock) — 4,980,055 Warrants to purchase common stock — 1,081,745 Warrants to purchase Series A-1 convertible preferred stock (as converted to common stock) — 154,022 Stock options to purchase common stock 2,159,001 856,555 Total 2,159,001 17,171,651

Organization and Operations (De

Organization and Operations (Details) - USD ($)	Jun. 30, 2021	Jun. 18, 2021	Jun. 30, 2021	Jun. 30, 2021	Mar. 08, 2019
Common Stock
Subsidiary, Sale of Stock [Line Items]
Conversion of convertible preferred shares into an equivalents number of common shares (in shares)	51,409	119,315	51,409	15,079,329
Conversion of Temporary Equity | Common Stock
Subsidiary, Sale of Stock [Line Items]
Conversion of convertible preferred shares into an equivalents number of common shares (in shares)		15,079,329
Conversion of Warrants | Common Stock
Subsidiary, Sale of Stock [Line Items]
Conversion of convertible preferred shares into an equivalents number of common shares (in shares)		1,201,059
IPO
Subsidiary, Sale of Stock [Line Items]
Number of shares sold in initial public offering (in shares)		7,666,664
Aggregate gross proceeds		$ 122,700,000
Net proceeds		$ 112,500,000
Over-Allotment Option
Subsidiary, Sale of Stock [Line Items]
Number of shares sold in initial public offering (in shares)		999,999
SGI | SGI-DNA, Inc.
Subsidiary, Sale of Stock [Line Items]
Non-recourse promissory note					$ 10,000,000

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details) $ in Thousands	Jun. 30, 2021USD ($)
Accounting Policies [Abstract]
Other current liabilities	$ 26

Fair Value Measurement - Assets

Fair Value Measurement - Assets and Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Contingent Put Option
Liabilities
Derivative liability	$ 100
Success fee contingent liability
Liabilities
Derivative liability	800	$ 500
Fair Value, Recurring
Assets
Total	123
Liabilities
Total	884	1,533
Fair Value, Recurring | Participation Rights
Liabilities
Derivative liability		420
Fair Value, Recurring | Warrant
Liabilities
Derivative liability		594
Fair Value, Recurring | Contingent Put Option
Liabilities
Derivative liability	134	51
Fair Value, Recurring | Success fee contingent liability
Liabilities
Derivative liability	750	468
Fair Value, Recurring | Money market funds
Assets
Money market funds	123
Fair Value, Recurring | Level 1
Assets
Total	123
Liabilities
Total	750	0
Fair Value, Recurring | Level 1 | Participation Rights
Liabilities
Derivative liability		0
Fair Value, Recurring | Level 1 | Warrant
Liabilities
Derivative liability		0
Fair Value, Recurring | Level 1 | Contingent Put Option
Liabilities
Derivative liability	0	0
Fair Value, Recurring | Level 1 | Success fee contingent liability
Liabilities
Derivative liability	750	0
Fair Value, Recurring | Level 1 | Money market funds
Assets
Money market funds	123
Fair Value, Recurring | Level 2
Assets
Total	0
Liabilities
Total	0	0
Fair Value, Recurring | Level 2 | Participation Rights
Liabilities
Derivative liability		0
Fair Value, Recurring | Level 2 | Warrant
Liabilities
Derivative liability		0
Fair Value, Recurring | Level 2 | Contingent Put Option
Liabilities
Derivative liability	0	0
Fair Value, Recurring | Level 2 | Success fee contingent liability
Liabilities
Derivative liability	0	0
Fair Value, Recurring | Level 2 | Money market funds
Assets
Money market funds	0
Fair Value, Recurring | Level 3
Assets
Total	0
Liabilities
Total	134	1,533
Fair Value, Recurring | Level 3 | Participation Rights
Liabilities
Derivative liability		420
Fair Value, Recurring | Level 3 | Warrant
Liabilities
Derivative liability		594
Fair Value, Recurring | Level 3 | Contingent Put Option
Liabilities
Derivative liability	134	51
Fair Value, Recurring | Level 3 | Success fee contingent liability
Liabilities
Derivative liability	0	$ 468
Fair Value, Recurring | Level 3 | Money market funds
Assets
Money market funds	$ 0

Fair Value Measurement - Narrat

Fair Value Measurement - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands	Jun. 30, 2021	Jun. 18, 2021	Jun. 30, 2021	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Conversion of convertible preferred shares into an equivalent number of common shares				$ (38,914)
Change in fair value of derivative liabilities				1,251	$ 574	$ 1,547	$ 667
Success fee contingent liability
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability	$ 800		$ 800	$ 800		800		$ 500
Common Stock
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Shares issued for warrant exercises (in shares)	51,409	119,315	51,409	15,079,329
Participation Rights
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants liability	$ 0		$ 0	$ 0		$ 0		$ 400
Percentage right	(3.00%)		(3.00%)	(3.00%)		(3.00%)
Preferred Stock Warrants
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of Series A-1 convertible preferred stock warrant (in dollars per share)								$ 3.87
Fair Value, Recurring | Success fee contingent liability
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability	$ 750		$ 750	$ 750		$ 750		$ 468

Fair Value Measurement - Quanti

Fair Value Measurement - Quantitative Inputs (Details)	Jun. 18, 2021	Dec. 31, 2020
Risk-free interest rate | SGI Preferred Stock Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input		0.001
Risk-free interest rate | Preferred Stock Warrants, 2021 Loan Agreement
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input	0.014
Expected volatility | SGI Preferred Stock Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input		0.836
Expected volatility | Preferred Stock Warrants, 2021 Loan Agreement
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input	0.560
Expected dividend yield | SGI Preferred Stock Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input		0
Expected dividend yield | Preferred Stock Warrants, 2021 Loan Agreement
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input	0
Expected term | SGI Preferred Stock Warrants
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input		2
Expected term | Preferred Stock Warrants, 2021 Loan Agreement
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Measurement input	9.7

Fair Value Measurement - Roll f

Fair Value Measurement - Roll forward of Level 3 Financial Instruments (Details) - USD ($) $ in Thousands	3 Months Ended
	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020
Participation Rights
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Fair value	$ 0	$ 390	$ 420
Extinguishment of liability	390	0
Issuance of liability		0
Change in fair value	0	(30)
Transfer out of Level 3 to Level 1	0
Warrant
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Fair value	0	1,114	594
Extinguishment of liability	2,770	0
Issuance of liability		322
Change in fair value	1,656	198
Transfer out of Level 3 to Level 1	0
Contingent Put Option
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Fair value	134	303	51
Extinguishment of liability	0	51
Issuance of liability		303
Change in fair value	(169)	0
Transfer out of Level 3 to Level 1	0
Success fee contingent liability
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Fair value	0	596	$ 468
Extinguishment of liability	0	0
Issuance of liability		0
Change in fair value	154	$ 128
Transfer out of Level 3 to Level 1	$ (750)

Inventory (Details)

Inventory (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Inventory Disclosure [Abstract]
Raw materials	$ 514	$ 299
Work in process and sub-assemblies	414	201
Finished goods	124	101
Total	$ 1,052	$ 601

Property and Equipment - Schedu

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Total	$ 1,617	$ 1,455
Less: Accumulated depreciation and amortization	(952)	(766)
Total property and equipment, net	665	689
Machinery and equipment
Property, Plant and Equipment [Line Items]
Total	1,552	1,315
Computer hardware and software
Property, Plant and Equipment [Line Items]
Total	6	6
Leasehold improvements
Property, Plant and Equipment [Line Items]
Total	59	32
Construction in progress
Property, Plant and Equipment [Line Items]
Total	$ 0	$ 102

Property and Equipment - Narrat

Property and Equipment - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 100	$ 100	$ 189	$ 208

Goodwill and Other Intangible_3

Goodwill and Other Intangible Assets - Narrative (Details) - USD ($)	1 Months Ended	3 Months Ended		6 Months Ended
	Apr. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill		$ 3,497,000		$ 3,497,000		$ 3,497,000
Goodwill, impairment		0	$ 0	0	$ 0
Finite-Lived Intangible Assets [Line Items]
Amortization expense		100,000	$ 100,000	225,000	$ 238,000
Technology
Finite-Lived Intangible Assets [Line Items]
Intangible assets		3,200,000		$ 3,200,000
Intangible asset useful life (in years)				7 years
Trade Name
Finite-Lived Intangible Assets [Line Items]
Intangible assets		$ 100,000		$ 100,000
Intangible asset useful life (in years)				3 years
Impairment of intangible assets	$ 100,000

Goodwill and Other Intangible_4

Goodwill and Other Intangible Assets - Schedule of Amortization Expense (Details) $ in Thousands	Jun. 30, 2021USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2021	$ 225
2022	450
2023	450
2024	450
2025	450
Thereafter	75
Total	$ 2,100

Leases - Narrative (Details)

Leases - Narrative (Details)	Jun. 30, 2021lease
Leases [Abstract]
Number of outstanding leases	3
Minimum
Lessee, Lease, Description [Line Items]
Term of leases (in months)	25 months
Term of leases (in months)	25 months
Maximum
Lessee, Lease, Description [Line Items]
Term of leases (in months)	60 months
Term of leases (in months)	60 months

Leases - Components of Lease Co

Leases - Components of Lease Cost (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Finance lease cost:
Payment of finance lease liability	$ 42	$ 54
Interest on lease liabilities	7	10
Amortization of right-of-use asset	315	290
Variable lease cost	251	161
Total lease cost	$ 615	$ 515

Leases - Cash Flow Information

Leases - Cash Flow Information (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Leases [Abstract]
Operating cash flows from operating leases	$ 478	$ 380
Operating cash flows from finance leases	7	10
Financing cash flows from finance leases	$ 42	$ 54

Leases - Weighted-Average Lease

Leases - Weighted-Average Lease Terms and Interest Rates (Details)	Jun. 30, 2021	Jun. 30, 2020
Leases [Abstract]
Finance leases, weighted average remaining lease term (in years)	1 year 6 months	2 years 2 months 12 days
Operating leases, weighted average remaining lease term (in years)	3 years 7 months 6 days	4 years 7 months 6 days
Finance leases, weighted average discount rate (as a percent)	7.70%	8.00%
Operating leases, weighted average discount rate (as a percent)	8.90%	8.90%

Leases - Minimum Future Lease P

Leases - Minimum Future Lease Payments (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Operating
2021	$ 489
2022	997
2023	1,026
2024	1,057
2025	89
Total future minimum lease payments	3,658
Less: imputed interest	(522)
Present value of operating lease liability	3,136
Less: current portion of lease liability	(739)	$ (693)
Non-current portion of lease liability	2,397	2,776
Finance
2021	44
2022	85
2023	0
2024	0
2025	0
Total future minimum lease payments	129
Less: imputed interest	(7)
Present value of operating lease liability	122
Less: current portion of lease liability	(83)	(90)
Non-current portion of lease liability	$ 39	$ 81

Notes Payable - Schedule of Lon

Notes Payable - Schedule of Long-term Debt (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Debt Disclosure [Abstract]
Principal amount of loans payable	$ 15,000	$ 5,000
Less: Current portion of loans payable	0	(1,333)
Loans payable, net of current portion	15,000	3,667
Accrued Interest	91	90
Final debt payment liability	400	287
Debt discount and financing costs, net of accretion	(1,006)	(691)
Loans payable, net of discount and current portion	$ 14,485	$ 3,353

Notes Payable - Narrative (Deta

Notes Payable - Narrative (Details) - USD ($)	Jun. 30, 2021	Jun. 18, 2021	Mar. 04, 2021	Sep. 05, 2019	Jun. 30, 2021	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Mar. 05, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Loss on extinguishment of debt						$ 0	$ 0	$ 618,000	$ 0
Final debt payment	$ 400,000				$ 400,000	400,000		400,000			$ 287,000
Success fee contingent liability
Debt Instrument [Line Items]
Derivative liability	800,000				800,000	800,000		800,000			$ 500,000
Contingent Put Option
Debt Instrument [Line Items]
Derivative liability	$ 100,000				$ 100,000	$ 100,000		$ 100,000
Common Stock
Debt Instrument [Line Items]
Shares issued for warrant exercises (in shares)	51,409	119,315			51,409	15,079,329
Preferred Warrant
Debt Instrument [Line Items]
Value of securities called by warrants			$ 200,000
Percent of advanced principal			1.50%
Line of Credit | Secured Debt | 2019 Loan and Security Agreement
Debt Instrument [Line Items]
Proceeds from issuance of debt				$ 5,000,000
Loss on extinguishment of debt				$ 600,000
Stated percentage rate (as a percent)				8.79%
Line of Credit | Secured Debt | 2019 Loan and Security Agreement | LIBOR
Debt Instrument [Line Items]
Basis spread on variable rate				6.38%
Line of Credit | Secured Debt | 2021 Loan Agreement
Debt Instrument [Line Items]
Proceeds from issuance of debt			$ 15,000,000
Stated percentage rate (as a percent)			7.25%
Interest rate at period end (as a percent)	10.40%				10.40%	10.40%		10.40%		7.25%
Debt extension term			1 year
Minimum revenue threshold			$ 4,000,000
Extension threshold period			3 months
Interest-only payments, minimum revenue threshold			$ 4,000,000
Final debt payment			400,000
Third-party indebtedness right threshold			$ 500,000
Debt default rate (as a percent)			5.00%
Line of Credit | Secured Debt | 2021 Loan Agreement | Debt Instrument, Redemption, Period One
Debt Instrument [Line Items]
Prepayment fee, percentage			3.00%
Line of Credit | Secured Debt | 2021 Loan Agreement | Debt Instrument, Redemption, Period Two
Debt Instrument [Line Items]
Prepayment fee, percentage			2.00%
Line of Credit | Secured Debt | 2021 Loan Agreement | Debt Instrument, Redemption, Period Three
Debt Instrument [Line Items]
Prepayment fee, percentage			1.00%
Line of Credit | Secured Debt | 2021 Loan Agreement | Prime Rate
Debt Instrument [Line Items]
Basis spread on variable rate			4.00%
Line of Credit | Secured Debt | 2021 Loan Agreement, Second Term Loan
Debt Instrument [Line Items]
Maximum borrowing capacity			$ 5,000,000

Notes Payable - Schedule of Mat

Notes Payable - Schedule of Maturities (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Debt Disclosure [Abstract]
2022	$ 2,500
2023	6,000
2024	6,000
2025	500
Principal amount of loans payable	$ 15,000	$ 5,000

Stock-Based Compensation - Narr

Stock-Based Compensation - Narrative (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Share-based Payment Arrangement [Abstract]
Stock-based compensation expense	$ 100,000	$ 10,000	$ 200,000	$ 25,000
Income tax benefit	0		$ 0
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted (in shares)			1,813,829
Weighted average grant date fair value (in USD per share)			$ 2.16
Unrecognized compensation expense	$ 3,800,000		$ 3,800,000
Period for recognition (in years)			3 years 4 months 24 days
2019 Stock Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for grant (in shares)	5,544,187		5,544,187
2021 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for future issuance (in shares)	6,000,000		6,000,000
Vesting period (in years)			4 years
Expiration period (in years)			10 years
2021 Stock Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for future issuance (in shares)	3,500,000		3,500,000
Stock options
Share-based Payment Arrangement [Abstract]
Stock-based compensation expense	$ 146,000		$ 213,000
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Purchase price of common stock at least (as a percent)			100.00%
Stock options | Over 10% Shareholder
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Purchase price of common stock at least (as a percent)			110.00%
Nonstatutory Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Purchase price of common stock at least (as a percent)			100.00%
ESPP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for future issuance (in shares)	350,000		350,000

Stock-Based Compensation - Stoc

Stock-Based Compensation - Stock Option activity (Details) $ / shares in Units, $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2021USD ($)$ / sharesshares	Dec. 31, 2020USD ($)$ / sharesshares
Number of options
Outstanding at beginning of the period (in shares) | shares	760,159
Options granted (in shares) | shares	1,813,829
Options exercised (in shares) | shares	(269,145)
Options cancelled (in shares) | shares	(145,842)
Outstanding at end of the period (in shares) | shares	2,159,001	760,159
Vested and expected to vest (in shares) | shares	2,159,001
Exercisable (in shares) | shares	82,300
Weighted average exercise price
Outstanding at beginning of period (in USD per share) | $ / shares	$ 0.60
Options granted (in USD per share) | $ / shares	5.51
Options exercised (in USD per share) | $ / shares	0.59
Options cancelled (in USD per share) | $ / shares	2.41
Outstanding at end of period (in USD per share) | $ / shares	4.83	$ 0.60
Vested and expected to vest (in USD per share) | $ / shares	4.83
Exercisable (in USD per share) | $ / shares	$ 0.51
Weighted average remaining contractual term (in years)
Outstanding (in years)	9 years 6 months	8 years 8 months 12 days
Options granted (in years)	9 years 9 months 18 days
Options exercised (in years)	8 years 1 month 6 days
Options cancelled (in years)	9 years 2 months 12 days
Vested and expected to vest (in years)	9 years 6 months
Exercisable (in years)	8 years
Aggregate intrinsic value (in thousands)
Outstanding | $	$ 37,071	$ 2,884
Options granted | $	29,419
Options exercised | $	5,763
Options cancelled | $	2,856
Vested and expected to vest | $	37,071
Exercisable | $	$ 1,769

Stock-Based Compensation - Fair

Stock-Based Compensation - Fair Value Assumptions (Details) - Stock options	6 Months Ended
	Jun. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	1.20%
Expected dividend yield	0.00%
Expected term	6 years 1 month 6 days
Expected volatility	38.80%

Stock-Based Compensation - Clas

Stock-Based Compensation - Classification of Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	$ 100	$ 10	$ 200	$ 25
Stock options
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	146		213
Research and development | Stock options
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	4		7
Sales and marketing | Stock options
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	15		30
General and administrative | Stock options
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Stock-based compensation expense	$ 127		$ 176

STOCKHOLDER'S EQUITY (Details)

STOCKHOLDER'S EQUITY (Details) - USD ($) $ in Millions	Jun. 30, 2021	Jun. 18, 2021	Jun. 30, 2021	Jun. 30, 2021
Common Stock
Subsidiary, Sale of Stock [Line Items]
Shares issued for warrant exercises (in shares)	51,409	119,315	51,409	15,079,329
Conversion of Temporary Equity | Common Stock
Subsidiary, Sale of Stock [Line Items]
Shares issued for warrant exercises (in shares)		15,079,329
Conversion of Warrants | Common Stock
Subsidiary, Sale of Stock [Line Items]
Shares issued for warrant exercises (in shares)		1,201,059
IPO
Subsidiary, Sale of Stock [Line Items]
Number of shares sold in initial public offering (in shares)		7,666,664
Aggregate gross proceeds		$ 122.7
Net proceeds		$ 112.5
Over-Allotment Option
Subsidiary, Sale of Stock [Line Items]
Number of shares sold in initial public offering (in shares)		999,999

Income Taxes (Details)

Income Taxes (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2021
Tax Credit Carryforward [Line Items]
Income tax expense (benefit)	$ 2,000	$ 0	$ 6,000	$ 0
Unrecognized tax benefits	$ 0		$ 0
Forecast
Tax Credit Carryforward [Line Items]
Effective income tax rate (as a percent)					0.00%

Commitment and Contingencies (D

Commitment and Contingencies (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Success fee contingent liability
Derivative [Line Items]
Derivative liability	$ 800	$ 500

Net Loss Per Share - Basic and

Net Loss Per Share - Basic and Diluted Earnings Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2021	Jun. 30, 2020
Numerator:
Net loss	$ (9,201)	$ (7,442)	$ (4,082)	$ (3,880)	$ (16,643)	$ (7,962)
Net loss attributable to common stockholders	$ (9,201)		$ (4,082)		$ (16,643)	$ (7,962)
Denominator:
Weighted average common stock outstanding - basic (in shares)	8,697,707		5,000,286		6,955,084	5,000,143
Weighted average common stock outstanding - diluted (in shares)	8,697,707		5,000,286		6,955,084	5,000,143
Net loss per share attributable to common stockholders - basic (in USD per share)	$ (1,060)		$ (820)		$ (2,390)	$ (1,590)
Net loss per share attributable to common stockholders - diluted (in USD per share)	$ (1,060)		$ (820)		$ (2,390)	$ (1,590)

Net Loss Per Share - Antidiluti

Net Loss Per Share - Antidilutive Securities (Details) - shares	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities (in shares)	2,159,001	17,171,651
Equity Unit Purchase Agreements | Series Z Convertible Preferred Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities (in shares)	0	2,500,000
Equity Unit Purchase Agreements | Series A Convertible Preferred Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities (in shares)	0	7,599,274
Equity Unit Purchase Agreements | Series A-1 Convertible Preferred Stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities (in shares)	0	4,980,055
Warrant | Common Stock Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities (in shares)	0	1,081,745
Warrant | Series A-1 Convertible Preferred Stock Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities (in shares)	0	154,022
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities (in shares)	2,159,001	856,555

Retirement Plan (Details)

Retirement Plan (Details) - USD ($)	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Retirement Benefits [Abstract]
Contribution costs	$ 0	$ 0

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Related Party Transactions [Abstract]
Payments to related parties	$ 0.1	$ 0.2